Anti-VEGF fusion protein indicated for age-related macular degeneration (AMD) and diabetic macular edema.
Aflibercept
Active Ingredient: Aflibercept
Indications for Aflibercept:
Aflibercept is indicated for the treatment of:
Neovascular AMD in patients over 60 years of age and diabetic macular edema.
Visual impairment due to macular edema secondary to retinal vein occlusion (central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO)).
Visual impairment due to diabetic macular edema (DME).
Visual impairment due to myopic choroidal neovascularization (myopic CNV).
Aflibercept is indicated in premature newborns for the treatment of:
Retinopathy of prematurity (ROP) Zone I (stage 1+, 2+, 3+, or 3+), Zone II (stages 2+ and 3+), or aggressive posterior ROP (AP-ROP).
Specifications
Type of medication:
Biological - fusion protein.
Mechanism of Action:
Anti-VEGF (angiogenesis inhibitor).
Therapeutic Area:
Ophthalmology.
Prescription required?
Sold by prescription only.
The responsible use of medications is essential for the safety and effectiveness of treatment. Self-medication can mask symptoms, cause adverse effects, and harm your health. Prescription medications should be used only under the guidance of a qualified healthcare provider.
